Host immune system receptors recognizing allogeneic HiCM-188 cells

Host immune system receptors recognizing allogeneic HiCM-188 cells refers to the collective group of host immune receptors, primarily T-cell receptors (TCRs) and B-cell receptors, that identify and respond to the non-self Human Leukocyte Antigens (HLA) present on allogeneic HiCM-188 cells (1.1.2, 1.4.4). HiCM-188 is an investigational cell therapy consisting of purified cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs), developed by HELP Therapeutics for the treatment of advanced heart failure (1.2.1, 1.3.1). Because these cells are allogeneic, the host's immune system naturally recognizes them as foreign, leading to potential immune-mediated rejection and destruction of the transplanted tissue (1.3.2, 1.4.4). To mitigate this, patients receiving HiCM-188 typically undergo a regimen of immunosuppressive drugs, such as tacrolimus and mycophenolate mofetil, which target the activation and proliferation of these host immune cells (1.3.2). Successful modulation of these receptors is critical for the long-term engraftment, survival, and functional integration of the cardiomyocytes into the recipient's heart (1.2.2, 1.4.1). Clinical trials have monitored the development of donor-specific antibodies as a biomarker for this recognition process (1.1.4, 1.4.4). The primary therapeutic challenge associated with this target is balancing the prevention of graft rejection with the risks of systemic immunosuppression, such as increased susceptibility to infection (1.3.2, 1.4.4).

Other names

Allorecognition receptorsTransplant rejection receptorsHost-versus-graft mediatorsAnti-HiCM-188 immune receptors

Immunosuppression to prevent host T-cell and B-cell recognition of allogeneic HLA antigens on HiCM-188 cells, thereby preventing graft rejection.